A multicentre, single-arm, stage II trial made to determine the effectiveness of single-agent vinflunine in individuals with advanced non-small-cell lung tumor (NSCLC) previously treated having a platinum-based routine. (full response+incomplete response), relating to customized WHO requirements was 7.8 months (95% CI: 4.6CNR). Median PFS was 2.six months (95% CI: 1.4C3.8), as well as the median… Continue reading A multicentre, single-arm, stage II trial made to determine the effectiveness